---
schema_version: "secwatch.filing_event.v1"
accession: "0001641489-23-000007"
form_type: "8-K"
ticker: "VTVT"
cik: "0001641489"
company_name: "vTv Therapeutics Inc."
filed_at: "2023-03-06T23:59:59+00:00"
generated_at: "2026-06-18T11:43:22.032073+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# vTv Therapeutics reports FY2022 net loss of $19.2M; advances TTP399 toward Phase 3

## Summary
- Net loss attributable to shareholders was $19.2M ($0.26/share) for FY2022 vs $13.0M ($0.21/share) in FY2021.
- Cash and cash equivalents at Dec 31, 2022: $12.1M, down from $13.4M a year earlier.
- Received ~$12.0M from G42 Investments in Feb 2023 via early promissory note payment at 3.75% discount.
- Appointed Steven Tuch as EVP/CFO (Dec 2022) and Elizabeth Keiley as EVP/General Counsel (Feb 2023).
- Preparing to initiate first of two Phase 3 trials of TTP399 for Type 1 diabetes in H2 2023.

## SEC filing metadata
- accession: 0001641489-23-000007
- form_type: 8-K
- ticker: VTVT
- cik: 0001641489
- company_name: vTv Therapeutics Inc.
- filed_at: 2023-03-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1641489/000164148923000007/0001641489-23-000007-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1641489/000164148923000007/vtvt-20230306.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641489-23-000007
- JSON: https://secwatch.observer/filing/0001641489-23-000007.json
- Plain text: https://secwatch.observer/filing/0001641489-23-000007.txt

## Key facts
- Earnings Releases
  vTv Therapeutics Inc. reported the fourth quarter and year ended December 31, 2022 results: net income Net loss attributable to vTv shareholders for the three months ended December 31, 2022, was $4.7 million or $0.06 per ba, EPS $0.06 per basic share.
  - Period: the fourth quarter and year ended December 31, 2022
  - Net income: Net loss attributable to vTv shareholders for the three months ended December 31, 2022, was $4.7 million or $0.06 per ba
  - EPS: $0.06 per basic share
  - Result: reported results
  source text: vTv Therapeutics Inc. issued a press release to announce its financial results for the fiscal year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1641489/000164148923000007/0001641489-23-000007-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.